Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A H Sarris

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Blood|September 1, 1996
Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosisA H Sarris, R Luthra, V Papadimitracopoulou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2001
Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapyA H Sarris, I Braunschweig, L J Medeiros, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1997
Long-range amplification of genomic DNA detects the t(2;5)(p23;q35) in anaplastic large-cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosisA H Sarris, R Luthra, V Papadimitracopoulou, et al.
Leukemia & Lymphoma|May 30, 2001
Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcomeA M Tsimberidou, A H Sarris, L J Medeiros, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphomaA H Sarris, A Younes, P McLaughlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1997
Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomasA H Sarris, D Daliani, R Ulmer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2000
Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC seriesA López-Guillermo, F Cabanillas, P McLaughlin, et al.
Blood|May 16, 1998
The clinical significance of molecular response in indolent follicular lymphomasA López-Guillermo, F Cabanillas, P McLaughlin, et al.
Leukemia & Lymphoma|March 28, 1998
Use of the international prognostic index and the tumor score to detect poor-risk patients with primary mediastinal large B-cell lymphoma: a study of 37 previously untreated patientsJ E Romaguera, J Rodríguez Díaz-Pavon, L Carías, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2000
Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trialA H Sarris, F Hagemeister, J Romaguera, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Blood|September 1, 1996
Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosisA H Sarris, R Luthra, V Papadimitracopoulou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2001
Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapyA H Sarris, I Braunschweig, L J Medeiros, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1997
Long-range amplification of genomic DNA detects the t(2;5)(p23;q35) in anaplastic large-cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosisA H Sarris, R Luthra, V Papadimitracopoulou, et al.
Leukemia & Lymphoma|May 30, 2001
Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcomeA M Tsimberidou, A H Sarris, L J Medeiros, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphomaA H Sarris, A Younes, P McLaughlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 1997
Interferon-inducible protein 10 as a possible factor in the pathogenesis of cutaneous T-cell lymphomasA H Sarris, D Daliani, R Ulmer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2000
Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC seriesA López-Guillermo, F Cabanillas, P McLaughlin, et al.
Blood|May 16, 1998
The clinical significance of molecular response in indolent follicular lymphomasA López-Guillermo, F Cabanillas, P McLaughlin, et al.
Leukemia & Lymphoma|March 28, 1998
Use of the international prognostic index and the tumor score to detect poor-risk patients with primary mediastinal large B-cell lymphoma: a study of 37 previously untreated patientsJ E Romaguera, J Rodríguez Díaz-Pavon, L Carías, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 26, 2000
Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trialA H Sarris, F Hagemeister, J Romaguera, et al.
Pageof 6